This page shows the latest Medivation news and features for those working in and with pharma, biotech and healthcare.
Talzenna was acquired by Pfizer as part of its $14bn takeover of Medivation in 2016, and earlier this month the company made another mid-range acquisition in cancer, agreeing to buy
The acquisition announced yesterday is the big pharma company's largest since it bought another oncology specialist, Medivation in 2016 for $14bn, and could help build a third cancer blockbuster franchise ... The 2016 Medivation buyout saw its value drop
rivals when trying to bolt on Medivation (which went to Pfizer) and Actelion (bought by Johnson &Johnson).
One M&A deal that did go through was the $14bn acquisition of Medivation in 2016, though many analysts say the big pharma company overpaid for the firm and its oncology
The company acquired the candidate when it bought out Medivation for $14bn in 2016, and needs to recoup its investment with a successful PARP competitor.
for Medivation and Actelion.
More from news
Approximately 15 fully matching, plus 37 partially matching documents found.
The latter includes its $11.4bn deal to buy Array Biopharma – the biggest for the group since its $14.3bn takeover of cancer specialist Medivation – that added two marketed drugs (Mektovi
Only August 2016 ($21.4bn, including $14bn for the Pfizer Medivation deal) came close. ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure for total (disclosed) upfront payments typically ranges between $1-6bn per month.
So the conclusion is that Pfizer is mainly expecting to generate value from Medivation's late stage oncology programme. ... Sanofi sought to take control of Medivation's board using a paper vote.
on. Following its rejection of the $9.3bn [$52.5 per share in cash, 36% premium] on the table from Sanofi, Medivation is now open to bids, encouraging competition. ... In the light of this, Sanofi has elected to go hostile and has filed with the SEC
Sanofi would like to merge with Medivation as it makes “strong strategic sense”. ... Unfortunately the Medivation CEO, David Hung, was not interested in a meeting or even hearing Sanofi's proposal.
More from intelligence
Approximately 1 fully matching, plus 10 partially matching documents found.
Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.
He has over 20 years of drug development and commercialisation experience, having previously worked as chief commercial officer for Medivation and in various senior management roles at Johnson &Johnson and Centocor.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...